Last reviewed · How we verify
NCT05985551: MagNeo
Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment
trial testing SLND or TAD by the magnetic technique (SPIO) in Breast Cancer in 114 participants. Participants enrolled and being followed up; not accepting new ones.
30 October 2026
Quick facts
| Lead sponsor | Uppsala University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 114 |
| Start date | 1 January 2020 |
| Primary completion | 30 October 2026 |
| Estimated completion | 30 October 2027 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- SLND or TAD by the magnetic technique (SPIO)
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Chemotherapy Effect — all drugs for Chemotherapy Effect →
- Sentinel Lymph Node — all drugs for Sentinel Lymph Node →
Sponsor
Uppsala University
Who can join
18 and older, any sex, with Breast Cancer or Chemotherapy Effect. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study was to assess the feasibility of SLND by superparamagnetic iron oxide nanoparticles (SPIO) in patients with early breast cancer planned for primary systemic therapy (PST) and whether this is affected by the timeframe of SPIO administration. For this, patients with cN0/1 disease planned for PST received radioisotope as per routine on the day of surgery or the day before, and SPIO was injected in an extended timeframe, at any point from the day of surgery to before the induction of PST. The main points to investigate are: 1. If the SPIO detection rate and concordance to the radiosotope are affected by time of SPIO injection 2. If the nodal yield and the accuracy of the procedure are affected
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
TME-Related Biomimetic Strategies Against Cancer.
Peng C, Xu Y, Wu J, Wu D, et al · · 2024 · cited 57× · PMID 38192633 · DOI 10.2147/ijn.s441135 -
Recent advances in the bench-to-bedside translation of cancer nanomedicines.
Liu Y, Zhang Y, Li H, Hu TY. · · 2025 · cited 27× · PMID 40041906 · DOI 10.1016/j.apsb.2024.12.007 -
Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines.
Maksymova L, Pilger YA, Nuhn L, Van Ginderachter JA. · · 2025 · cited 24× · PMID 40033293 · DOI 10.1186/s12943-025-02270-5 -
Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer.
Oehler JB, Rajapaksha W, Albrecht H. · · 2024 · cited 16× · PMID 39063977 · DOI 10.3390/jpm14070723 -
Magnetically guided surgery after primary systemic therapy for breast cancer: implications for enhanced axillary mapping.
Pantiora E, Eriksson S, Wärnberg F, Karakatsanis A. · · 2024 · cited 8× · PMID 38325801 · DOI 10.1093/bjs/znae008 -
Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials.
Wu L, He C, Zhao T, Li T, et al · · 2024 · cited 6× · PMID 38918821 · DOI 10.1186/s12951-024-02644-9 -
Iron oxide nanoparticles: a versatile nanoplatform for the treatment and diagnosis of ovarian cancer.
Poonia N, Kumar V, Subudhi RN, Dalabehera M, et al · · 2025 · cited 2× · PMID 39722582 · DOI 10.1080/20415990.2024.2442301
Verify or expand the search:
- PubMed search for NCT05985551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Uppsala University trials
Trials by the same sponsor.
- NCT07517185 — The HIt HArd and hiT Early in Multiple Sclerosis Trial · Phase 2 · not yet recruiting
- NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
- NCT07461636 — Robotic-Assisted Pedicle Screw Placement in Spine Surgery · recruiting
- NCT07273409 — Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not · NA · recruiting
- NCT07352683 — Open TAP-block in Pediatric Abdominal Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05985551 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uppsala University
- Last refreshed: 3 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05985551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing